Since TweakR is overexpressed in multiple tumors, such as breast cancer, lung cancer, ovarian cancer, glioma, and endometrial cancer [10–15], several functional anti-TweakR antibodies have been investigated for treating cancers [16]. Here, TNFRSF12A is linked to glioma.